{"title":"Sales of Brand-Name Products and Generic Competitors Before and After Market Entry of Product Line Extensions in Canada","authors":"H. Xue, Ho-lun Wong, Patrick Wong, T. Einarson","doi":"10.3109/J058V17N03_03","DOIUrl":null,"url":null,"abstract":"ABSTRACTWe examined the success of product line extensions (PLEs) in Canada by studying five selected drugs, three with generic competitors (ciprofloxacin, fenofibrate, paroxetine) and two without (clarithromycin, tolterodine). Third-party prescription claims from Canada were used to examine market behavior, which was analyzed using multiple regression and ARIMA. Consistent negative associations indicated high substitutability for all products and their generics. However, this was found only for PLEs with distinct advantages (e.g., increased bioavailability, fewer side effects). PLEs may recapture some market share lost to generics, but success is product-specific and likely depends on the extent of the PLE's therapeutic advantage over the originator.","PeriodicalId":16734,"journal":{"name":"Journal of Pharmaceutical Marketing & Management","volume":"18 1","pages":"19-37"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Marketing & Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/J058V17N03_03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
ABSTRACTWe examined the success of product line extensions (PLEs) in Canada by studying five selected drugs, three with generic competitors (ciprofloxacin, fenofibrate, paroxetine) and two without (clarithromycin, tolterodine). Third-party prescription claims from Canada were used to examine market behavior, which was analyzed using multiple regression and ARIMA. Consistent negative associations indicated high substitutability for all products and their generics. However, this was found only for PLEs with distinct advantages (e.g., increased bioavailability, fewer side effects). PLEs may recapture some market share lost to generics, but success is product-specific and likely depends on the extent of the PLE's therapeutic advantage over the originator.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
